Ignite Creation Date:
2025-12-25 @ 2:04 AM
Ignite Modification Date:
2025-12-26 @ 12:29 AM
Study NCT ID:
NCT05500560
Status:
COMPLETED
Last Update Posted:
2023-07-25
First Post:
2022-07-30
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Effect of COVID-19 on Endothelial Function
Sponsor:
University Hospital of Patras
Organization:
Study Overview
Official Title:
Effect of COVID-19 on Endothelial Function
Status:
COMPLETED
Status Verified Date:
2023-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
COVID-19 disease (coronavirus disease 2019) primarily affects the respiratory system, using the angiotensin-converting enzyme 2 receptor. However, there is increasing evidence that COVID-19 can also affect the heart (myocardial injury, myocarditis, arrhythmias) and the vascular system, effects that may worsen the clinical outcome of patients.
The aim of this study is to assess the effect of COVID-19 on the patients' endothelial function, during the acute phase of the disease (inpatient), shortly after recovery (2 months) and in the mid-term (6 months). Evaluation of endothelial function will be performed non-invasively by the method of Peripheral Arterial Tonometry (PAT) using the EndoPAT2000 system (Itamar Medical, Israel).
This is a prospective, case-controlled, single-center clinical observational study.
The study will include adult patients who developed COVID-19 disease for whom admission for hospitalization was required, while the control group will consist of healthy volunteers matched for age, gender and cardiovascular risk factors.
Patients enrolled in the study will undergo the following visits:
* Visit 1: Hospitalization
* Visit 2: 2 months after discharge
* Visit 3: 6 months after discharge
* Visit 4: 1 year after discharge Patients will be subjected to measurement of the reactive hyperemia index with the EndoPAT2000 system in Visits 1, 2 and 3.
The aim of the study is to compare the endothelial function between the two groups (COVID-19 vs. Controls).
The aim of this study is to assess the effect of COVID-19 on the patients' endothelial function, during the acute phase of the disease (inpatient), shortly after recovery (2 months) and in the mid-term (6 months). Evaluation of endothelial function will be performed non-invasively by the method of Peripheral Arterial Tonometry (PAT) using the EndoPAT2000 system (Itamar Medical, Israel).
This is a prospective, case-controlled, single-center clinical observational study.
The study will include adult patients who developed COVID-19 disease for whom admission for hospitalization was required, while the control group will consist of healthy volunteers matched for age, gender and cardiovascular risk factors.
Patients enrolled in the study will undergo the following visits:
* Visit 1: Hospitalization
* Visit 2: 2 months after discharge
* Visit 3: 6 months after discharge
* Visit 4: 1 year after discharge Patients will be subjected to measurement of the reactive hyperemia index with the EndoPAT2000 system in Visits 1, 2 and 3.
The aim of the study is to compare the endothelial function between the two groups (COVID-19 vs. Controls).
Detailed Description:
1. Introduction COVID-19 disease (coronavirus disease 2019) primarily affects the respiratory system, using the angiotensin-converting enzyme 2 receptor. However, there is increasing evidence that COVID-19 can also affect the heart (myocardial injury, myocarditis, arrhythmias) and the vascular system, effects that may worsen the clinical outcome of patients.
Regarding COVID-19, there is increasing evidence of endothelial dysfunction, both directly due to direct infection of the vascular endothelium by the SARS-COV-2 virus (endothelitis), and indirectly due to the systemic inflammatory response and cascade of cytokines.
In the context of this study, the evaluation of endothelial function will be performed non-invasively by the method of Peripheral Arterial Tonometry (PAT) using the EndoPAT2000 system (Itamar Medical, Israel). The EndoPAT system quantifies the endothelium-dependent pulsatile arterial volume changes. During the examination, plethysmography biosensors are placed in the right and left patient's index fingers. Subsequently, arterial tone is measured in three phases:
A. at rest (baseline) B. during ischemia caused by a cuff inflated in one of the two arms at a level above that of systolic blood pressure for a period of 5 minutes C. during the phase of reactive hyperemia after the lifting of the arterial blockade by deflating the cuff The arterial tone signals detected in the above phases of the examination by the plethysmography biosensors are converted into digital signals for each upper limb and the EndoPAT2000 system software finally calculates the hyperemic vascular response (Ln Reactive Hyperemia Index-LnRHI). Endothelial dysfunction is defined as LnRHI≤0.51.
2. Aim of the study The aim of this study is to assess the effect of COVID-19 on the patients' endothelial function, during the acute phase of the disease (inpatient), shortly after recovery (2 months) and in the mid-term (6 months).
3. Methods This is a prospective, case-controlled, single-center clinical observational study.
The study will include adult patients who developed COVID-19 disease for whom admission for hospitalization was required, while the control group will consist of healthy volunteers matched for age, gender and cardiovascular risk factors.
Based on the limited existing data, patients in the COVID group are expected to have an average LnRHI of 0.58 (SD 0.25) at 2 months after discharge versus an average LnRHI of 0.79 in the control group. By selecting α=0.05, power=90% and enrollment ratio=1, the inclusion of 30 patients in each group is required to detect the above difference (60 in total).
Patients enrolled in the study will undergo the following visits:
* Visit 1: Hospitalization
* Visit 2: 2 months after discharge
* Visit 3: 6 months after discharge
* Visit 4: 1 year after discharge Patients will be subjected to measurement of the reactive hyperemia index with the EndoPAT2000 system in Visits 1, 2 and 3.
For all participants, the following will also be recorded:
* Demographics, cardiovascular risk factors, past medical history, chronic medical treatment
* Body weight, body mass index (BMI), systolic and diastolic blood pressure, resting heart rate
* Laboratory testing: Ht, Hgb, PLT, WBC, Ur, Cr, K, Na, SGOT, SGPT, UA, total cholesterol, LDL cholesterol, small dense LDL cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, fasting glucose, HbA1c, insulin, hsCRP, thyroid function check (TSH, T3, fT4), hs Troponin I
* ECG
* Thansthoracic ultrasound study (LVEF, GLS, parameters of diastolic function)
* Thrombotic complications, cardiovascular events, hospitalizations
Regarding COVID-19, there is increasing evidence of endothelial dysfunction, both directly due to direct infection of the vascular endothelium by the SARS-COV-2 virus (endothelitis), and indirectly due to the systemic inflammatory response and cascade of cytokines.
In the context of this study, the evaluation of endothelial function will be performed non-invasively by the method of Peripheral Arterial Tonometry (PAT) using the EndoPAT2000 system (Itamar Medical, Israel). The EndoPAT system quantifies the endothelium-dependent pulsatile arterial volume changes. During the examination, plethysmography biosensors are placed in the right and left patient's index fingers. Subsequently, arterial tone is measured in three phases:
A. at rest (baseline) B. during ischemia caused by a cuff inflated in one of the two arms at a level above that of systolic blood pressure for a period of 5 minutes C. during the phase of reactive hyperemia after the lifting of the arterial blockade by deflating the cuff The arterial tone signals detected in the above phases of the examination by the plethysmography biosensors are converted into digital signals for each upper limb and the EndoPAT2000 system software finally calculates the hyperemic vascular response (Ln Reactive Hyperemia Index-LnRHI). Endothelial dysfunction is defined as LnRHI≤0.51.
2. Aim of the study The aim of this study is to assess the effect of COVID-19 on the patients' endothelial function, during the acute phase of the disease (inpatient), shortly after recovery (2 months) and in the mid-term (6 months).
3. Methods This is a prospective, case-controlled, single-center clinical observational study.
The study will include adult patients who developed COVID-19 disease for whom admission for hospitalization was required, while the control group will consist of healthy volunteers matched for age, gender and cardiovascular risk factors.
Based on the limited existing data, patients in the COVID group are expected to have an average LnRHI of 0.58 (SD 0.25) at 2 months after discharge versus an average LnRHI of 0.79 in the control group. By selecting α=0.05, power=90% and enrollment ratio=1, the inclusion of 30 patients in each group is required to detect the above difference (60 in total).
Patients enrolled in the study will undergo the following visits:
* Visit 1: Hospitalization
* Visit 2: 2 months after discharge
* Visit 3: 6 months after discharge
* Visit 4: 1 year after discharge Patients will be subjected to measurement of the reactive hyperemia index with the EndoPAT2000 system in Visits 1, 2 and 3.
For all participants, the following will also be recorded:
* Demographics, cardiovascular risk factors, past medical history, chronic medical treatment
* Body weight, body mass index (BMI), systolic and diastolic blood pressure, resting heart rate
* Laboratory testing: Ht, Hgb, PLT, WBC, Ur, Cr, K, Na, SGOT, SGPT, UA, total cholesterol, LDL cholesterol, small dense LDL cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, fasting glucose, HbA1c, insulin, hsCRP, thyroid function check (TSH, T3, fT4), hs Troponin I
* ECG
* Thansthoracic ultrasound study (LVEF, GLS, parameters of diastolic function)
* Thrombotic complications, cardiovascular events, hospitalizations
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: